NASDAQ stock price data

Monopar Therapeutics Stock Surges 137% After Agreement for ALXN-1840, Phase 3 Drug for Wilson Disease

Oct 24, 2024, 04:08 PM

Monopar Therapeutics (NASDAQ: MNPR) has announced a significant agreement with Alexion Pharmaceuticals and AstraZeneca Rare Disease for its late-stage drug candidate targeting Wilson Disease. Following the announcement, Monopar's stock surged approximately 137%, prompting a trading halt due to volatility. The agreement grants Monopar an exclusive worldwide license to ALXN-1840, a drug candidate for Wilson Disease that has already completed a Phase 3 clinical trial. The stock was up about 20% ahead of Thursday's trading session, reflecting investor optimism regarding the potential of the drug and the strategic collaboration with Alexion and AstraZeneca.